Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVC-203
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : ViroCell Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
ViroCell and AvenCell Announce Retroviral Vector Manufacturing Collaboration
Details : The collaboration with ViroCell will help manufacture CAR-T cell therapy products, including AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B-cell malignancies.
Product Name : AVC-203
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 29, 2025
Lead Product(s) : AVC-203
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : ViroCell Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Organovo Holdings
Deal Size : $112.0 million
Deal Type : Series B Financing
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
Details : The proceeds will accelerate AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, including AVC-101, for a wide range of hematologic malignancies and auto-immune diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : AVC-101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Organovo Holdings
Deal Size : $112.0 million
Deal Type : Series B Financing
Details : R-TM123 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 17, 2023
Details : AVC-101 is a CD-123-directed cell therapy targeting acute myeloid leukemia, that utilizes AvenCell’s proprietary Universal Targeting platform, a regulatable CAR T cell technology that can turn CAR T cells “OFF” and “ON” by means of separately i...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : PHARMALOG Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : PHARMALOG Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : PHARMALOG Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : PHARMALOG Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GEM3PSCA is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 25, 2019
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
Details : GEM333 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 04, 2018
Reset All
